# US 2012/0232028 A1 · Bicyclic Compound, Production and Use Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232028 A1
- Document ID: US20120232028A1
- Status: Published application
- Kind: A1
- Application number: 13/476,454
- Filed: 2012-05-21
- Published: 2012-09-13
- Earliest claimed: 2001-08-08
- Assignees: Tobira Therapeutics, Inc.
- Inventors: Mitsuru SHIRAISHI; Masanori BABA; Katsuji AIKAWA; Naoyuki KANZAKI; Masaki SETO; Yuji IIZAWA
- Web page: https://patentgrep.com/patent/US20120232028A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 225/06: condensed with one six-membered ring
- C07D 313/20: condensed with carbocyclic rings or ring systems
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a new cyclic compound having a CCR antagonist activity, especially a CCR5 antagonist activity, and the use thereof. The compound of the present invention is represented by the formula: wherein, R1 is a 5- to 6-membered ring group which may be substituted; X1 is a bond or the like; ring A is a 5- to 6-membered ring group which may be substituted; ring B is a 8- to 10-membered ring group which may be substituted; X2 is a bivalent group of 1 to 4 atoms; Z1 is a bivalent cyclic ring group or the like; Z2 is a bond or the like; and R2 is an amino group, a nitrogen-containing heterocyclic group which may be substituted or the like, or a salt thereof.

## Claims

### Claim 1

A compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt thereof, provided that a compound of the formula:
wherein ring A1 is a benzene ring which may be substituted; Y1 is a bivalent group so that ring B1 forms a 8-membered ring; Q1 is a group of the formula:
wherein X is a bond or a bivalent group; and R1 and R2 are the same or different and each is hydrogen, or a lower alkyl group, or may bind each other to form a ring; and
Q2 is hydrogen, a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, is excluded.

### Claim 2 (depends on 1)

A pro-drug of the compound of claim 1.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 is benzene, furan, thiophene, pyridine, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine, or tetrahydropyran, each of which may be substituted.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 is benzene which may be substituted.

### Claim 5 (depends on 1)

The compound of claim 1, wherein ring B is a 8-membered ring which may be substituted.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Z1 is phenylene which may be substituted with substituent(s) selected from the group consisting of (1) a halogen atom; (2) an alkyl group of 1 to 4 carbons which may be substituted with halogen atom(s); and (3) an alkoxy group of 1 to 4 carbons which may be substituted with halogen atom(s).

### Claim 7 (depends on 1)

The compound of claim 1, wherein Z1 is phenylene which may be substituted with methyl or trifluoromethyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein Z2 is —Z2a—W1—Z2b— wherein, each of Z2a and Z2b is O, S(O)m (wherein m is 0, 1, or 2), an imino group which may be substituted, or a bond; W1 is an alkylene chain which may be substituted, an alkenylene chain, or a bond.

### Claim 9 (depends on 1)

The compound of claim 1, wherein Z2 is —CH2—, —CH(OH)—, or —S(O)m—CH2— (wherein m is 0, 1, or 2).

### Claim 10 (depends on 1)

The compound of claim 1, wherein Z2 is —S(O)m—CH2— (wherein m is 0, 1 or 2).

### Claim 11 (depends on 1)

The compound of claim 1, wherein R2 is (1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide, (2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide, (3) an amidino group which may be substituted, or (4) a guanidino group which may be substituted.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R2 is an amino group which may be substituted or a nitrogen-containing heterocyclic group which may be substituted and may contain a sulfur atom or an oxygen atom as a ring constituent atom.

### Claim 13 (depends on 1)

The compound of claim 1, wherein R2 is a group of —NRR′ (wherein each of R and R′ is an aliphatic hydrocarbon group which may be substituted, or an alicyclic heterocyclic group which may be substituted).

### Claim 14 (depends on 1)

The compound of claim 1, wherein R2 is a nitrogen-containing aromatic heterocylic group which may substituted.

### Claim 15 (depends on 1)

The compound of claim 1, wherein R2 is imidazolyl group which may be substituted or triazolyl group which may be substituted.

### Claim 16 (depends on 1)

The compound according to claim 1, wherein
R1 is benzene, furan, thiophene, pyridine, cyclopentane, cyclohexane, pyrrolidine, piperidine, piperazine, morpholine, thiomorpholine or tetrahydropyran each or which may be substituted with halogen, nitro, cyano, C1-6alkyl, C1-6 alkoxy, C1-6 alkoxy-C1-6 alkyl or C1-6 alkoxy-C1-6 alkoxy,
ring B is 8- to 10-membered ring which may contain oxygen atom, nitrogen atom or sulfur atom which may be oxidized as a ring constituent atom and may be substituted with alkyl which may be substituted, alkenyl which may be substituted, a heterocyclic group which may be substituted or formyl,
Z1 is benzene which may be substituted with substituent(s) selected from (1) halogen, (2) C1-4 alkyl which may be halogenated and (3) C1-4 alkoxy which may be halogenated,
Z2 is —Z2a—W1—Z2b—, wherein Z2a and Z2b are O, S(O)m (m is 0, 1 or 2), imino which may be substituted with C1-4 alkyl or a bond, respectively, W1 is a bond or C1-4 alkylene or C2-4 alkenylene chain each of which may be substituted with C1-6 alkyl, hydroxy, hydroxyimino or C1-6 alkoxyimino, and
R2 is an amino group which may be substituted with C1-4 alkyl, or a nitrogen-containing heterocyclic group which may be substituted with C1-4 alkyl, may contain a sulfur or oxygen atom as a ring constituent atom.

### Claim 17 (depends on 1)

A compound of the formula:
wherein
Z1a is a 5- or 6-membered aromatic ring group;
Z2′ is a group of —Z2a—W2—Z2b— (wherein each of Z2a and Z2b is O, S(O)m (wherein m is 0, 1, or 2), an imino group which may be substituted, or a bond; and W2 is a alkylene chain which may be substituted);
n is 1, 2, or 3;
Y is O, S(O)p (wherein p is 0, 1, or 2), CH2, or NR4 (R4 is hydrogen, a hydrocarbon group which may be substituted, a heterocyclic group which may be substituted or an acyl group which may be substituted); and
R2′ is (1) an amino group which may be substituted and whose nitrogen atom may be converted to quaternary ammonium or oxide; (2) a nitrogen-containing heterocyclic group which may be substituted and may contain a sulfur atom or an oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide; (3) an amidino group which may be substituted; (4) a guanidino group which may be substituted; and
R1 is as described in claim 1, or a salt thereof.

### Claim 18

A compound of the formula:
wherein
R1 is (C1-6 alkoxy-C1-6 alkoxy)phenyl,
R2 is (1) N—C1-6 alkyl-N-tetrahydropyranylamino, (2) imidazolyl which may be substituted with C1-6 alkyl which may be substituted, or (3) triazolyl which may be substituted with C1-6 alkyl which may be substituted,
R3 is hydrogen, a lower alkyl group which may be substituted, or a lower alkoxy group which may be substituted,
Ya is (1) oxygen atom, (2) S(O)p (p is 0, 1, or 2), (3) CH2 or (4) imino which may be substituted with formyl, C1-6 alkyl which may be substituted, C2-6alkenyl which may be substituted, aryl which may be substituted, a heterocyclic group which may be substituted, arylmethyl which may be substituted or a heterocyclic methyl which may be substituted,
n is 1, 2 or 3,
na is 0 or 1, and
Z2a is a bond, S, SO or SO2, or a salt thereof.

### Claim 19 (depends on 18)

The compound of claim 18, wherein Z2a is SO.

### Claim 20 (depends on 18)

The compound of claim 18, wherein Z2a is SO whose configuration is (S).

### Claim 21 (depends on 18)

The compound of claim 18, wherein Ya is imino which may be substituted with formyl, C1-6 alkyl which may be substituted, C2-6 alkenyl which may be substituted, aryl which may be substituted; a heterocyclic group which may be substituted, arylmethyl which may be substituted or a heterocyclic methyl which may be substituted.

### Claim at position 22

-27. (canceled)

### Claim 28 (depends on 1)

A process for producing a compound of the formula:
wherein R2″ is
(1) an amino group which may be substituted and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted and may contain a sulfur atom or an oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide, or
(3) a compound represented by the formula:
wherein k is 0, or 1, when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 may be a hydrocarbon group which may be substituted, a hydroxy group, or an amino group which may be substituted; and R5 and R6 may bind each other with the adjacent phosphorus atom to form a cyclic group; and the other symbols are as defined in claim 1 or a salt thereof, provided that a compound of the formula:
wherein each symbol is as defined in claim 1 is excluded, which comprises subjecting a compound represented the formula:
wherein each symbol is as defined in claim 1, provided that a compound represented by the formula:
wherein each symbol is as defined in claim 1 is excluded, or a salt thereof or a derivative thereof, and a compound represented by the formula:
H2N—Z1—Z2—R2″
wherein R2″ is as defined above; Z1 and Z2 are as defined in claim 1, or salt thereof, provided that a compound represented by the formula:
wherein each symbol is as defined in claim 1 is excluded, to a condensation reaction, and then optionally to deprotection, oxidation/reduction or quaternary ammonium formation reaction.

### Claim 29 (depends on 1)

A compound of the formula:
wherein R3 is hydrogen, a halogen atom, a lower alkyl group which may be substituted, or a lower alkoxy group which may be substituted; and the other symbols are as defined in claim 1, or a salt thereof, provided that a compound represented by the formula:
wherein each symbol is as defined in claim 1 is excluded.

### Claim 30

A CCR antagonist pharmaceutical composition comprising a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt or prodrug thereof.

### Claim 31 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a salt or prodrug thereof.

### Claim 32 (depends on 31)

The composition of claim 31 which is a CCR antagonist.

### Claim 33 (depends on 30)

The composition of claim 30, wherein CCR is CCR 5 and/or CCR 2.

### Claim 34 (depends on 30)

The composition of claim 30, wherein CCR is CCR5.

### Claim 35 (depends on 30)

The composition of claim 30 which is a medicine for preventing or treating HIV infectious diseases, chronic rheumatoid arthritis, autoimmune disease, allergic diseases, ischemic brain cell disorder, cardiac infarction, chronic nephritis or arteriosclerosis.

### Claim 36 (depends on 30)

The composition of claim 30 which is a medicine, for preventing or treating HIV infectious diseases.

### Claim 37 (depends on 30)

The composition of claim 30 which is a medicine for preventing or treating AIDS.

### Claim 38 (depends on 30)

The composition of claim 30 which is a medicine for suppression on disease progression of AIDS.

### Claim 39 (depends on 30)

The composition of claim 30 which is blood for transfusion or blood derivatives.

### Claim 40 (depends on 30)

The composition of claim 30 which is a medicine for preventing or treating graft versus host disease and/or rejection in case of organ or bone marrow transplantation.

### Claim 41 (depends on 30)

The composition of claim 30 in combination with a protease inhibitor and/or a reverse transcriptase inhibitor.

### Claim 42 (depends on 41)

The composition of claim 41, wherein the reverse transcriptase inhibitor is zidovudine, didanosine, zaicitabine, lamivudine, stavudine, nevirapine, delavirdine, efavirenz, or abacavir.

### Claim 43 (depends on 41)

The composition of claim 41, wherein the protease inhibitor is saquinavir, ritonavir, indinavir, amprenavir, or nelfinavir.

### Claim 44

A method for antagonizing CCR5 which comprises administering an effective amount of a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt or prodrug thereof, to a mammal in need thereof.

### Claim 45 (depends on 44)

The method of claim 44, wherein a protease inhibitor and/or a reverse transcriptase inhibitor is further administered.

### Claim 46

A method for preventing or treating HIV infectious disease, chronic rheumatoid arthritis, autoimmune disease, allergic disease, ischemic brain cell disorder, cardiac infarction, chronic nephritis or arteriosclerosis which comprises administering an effective amount of a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt or prodrug thereof, to a mammal in need thereof.

### Claim 47

A method for preventing or treating graft versus host disease and/or rejection in case of organ or bone marrow transplantation which comprises administering an effective amount of a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt or prodrug thereof, to a mammal in need thereof.

### Claim 48

A method for preventing HIV infectious disease in case of transfusion or using blood derivatives which comprises administering an effective amount of a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt or prodrug thereof.

### Claim 49 (depends on 48)

The method of claim 48, wherein the compound is administered at the same time of or within 1 hour after transfusion or use of blood derivatives.

### Claim 50

A process for producing blood for transfusion or blood derivatives prevented or inhibited from infection of HIV virus and proliferation thereof which comprises compounding the blood for transfusion or blood derivatives with a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt thereof.

### Claim 51

A method for preventing or inhibiting infection of HIV virus and proliferation thereof in blood for transfusion or blood derivatives which comprises compounding the blood for transfusion or blood derivatives with a compound of the formula:
wherein
R1 is a cyclic 5- to 6-membered ring which may be substituted;
X1 is a bond or a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
ring A is a 5- to 6-membered ring which may be substituted;
ring B is a 8- to 10-membered ring which may be substituted;
each of E1 and E4 is a carbon atom which may be substituted or a nitrogen atom which may be substituted;
each of E2 and E3 is a carbon atom which may be substituted, a nitrogen atom which may be substituted, a sulfur atom which may be oxidized, or an oxygen atom;
each of a and b is a single bond or a double bond;
X2 is a bivalent chain group whose straight chain moiety is constituted of 1 to 4 atoms;
Z1 is a bond or a bivalent cyclic group;
Z2 is a bond or a bivalent group; and
R2 is
(1) an amino group which may be substituted and whose nitrogen atoms may be converted to quaternary ammonium or oxide,
(2) a nitrogen-containing heterocyclic group which may be substituted, may contain a sulfur or oxygen atom as a ring constituent atom, and whose nitrogen atom may be converted to quaternary ammonium or oxide,
(3) a group of the formula:
wherein k is 0 or 1; when k is 0, the phosphorus atom may form a phosphonium salt; each of R5 and R6 is a hydrocarbon group which may be substituted, a hydroxy group or an amino group which may be substituted; and R5 and R6 may form a ring with the adjacent phosphorus atom,
(4) an amidino group which may be substituted, or
(5) a guanidino group which may be substituted; or a salt thereof.

### Claim at position 47

-56. (canceled)
